NCT01378416View on ClinicalTrials.gov

Pharmacokinetic Trial of Decitabine (Dacogen) Administered as a 3-hour Infusion to Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

April 30, 2005

Primary Completion Date

January 31, 2006

Study Completion Date

June 30, 2007

Conditions
Leukemia
Interventions
DRUG

Decitabine (Dacogen)

Intravenous injection; total dose-per-cycle was 135 mg/m\^2 of decitabine.

Trial Locations (1)

63110

Washington University School of Medicine, St Louis

All Listed Sponsors
lead

Eisai Inc.

INDUSTRY

NCT01378416 - Pharmacokinetic Trial of Decitabine (Dacogen) Administered as a 3-hour Infusion to Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome | Biotech Hunter | Biotech Hunter